Skip to content

Use of a c-Met-targeting aptamer-drug conjugate for efficient therapy in both primary and metastatic uveal melanoma.

Nov 2026 · Biomaterials · Vol 339, pp. 124736 · 0 citations · 56 references
Medicine

Abstract

Uveal melanoma (UM), the most common primary intraocular malignancy in adults, is associated with a high risk of metastasis, recurrence, and irreversible vision loss. However, current therapeutic options remain limited by insufficient efficacy and poor vision preservation. Building upon the molecular design of SL1-MMAE, a c-Met-targeting aptamer-drug conjugate (ApDC), here we investigate its potential translational application as a targeted therapeutic strategy for both primary and metastatic UM. SL1-MMAE exhibits high binding specificity, rapid cellular internalization, and potent cytotoxicity toward UM cells in vitro. In vivo, SL1-MMAE effectively suppresses tumor growth in both subcutaneous xenograft and liver metastasis models, significantly prolonging survival. Notably, in an orthotopic intraocular UM model, a single intravitreal injection of SL1-MMAE induces robust tumor regression without detectable ocular toxicity at the therapeutic dose. The small molecular size of the ApDC enables superior tumor penetration and reduced retention from non-target ocular tissues. These features are particularly advantageous within the confined intraocular environment, leading to enhanced therapeutic efficacy with improved safety. Compared with the clinically advanced c-Met antibody-drug conjugate (ADC) ABBV-399, the ApDC demonstrates superior antitumor activity and ocular biocompatibility for intraocular UM therapy. Nevertheless, as a preclinical study, further safety, pharmacokinetic and translational studies are warranted to better define the clinical potential of SL1-MMAE. Collectively, these findings establish c-Met-targeting ApDCs as a promising platform for the treatment of both primary and metastatic UM, offering a vision-preserving therapeutic strategy with potent antitumor efficacy and favorable safety profiles.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.